Abstract
In 2009 the Infectious Diseases Society of America reviewed the guidelines on the treatment of candidemia in non-neutropenic patients. In this document the preferred treatment was either fluconazole or an echinocandin. Amphotericin-B formulations were considered an alternative. However, careful assessment of published data showed similar efficacy between these drugs.
Highlights
Fungal infections, in particular candidemia, are a growing problem in immunocompetent patients [1]
Concern exists on the value of evidence supporting recommendations for the optimal treatment of candidemia in non-neutropenic adult patients [1,2]
The new evidence A recent study from Reboli and colleagues [6] suggests that anidulafungin might be superior to fluconazole as primary therapy for candidemia in non-neutropenic patients (75.6% success with anidulafungin compared to 60.2% with fluconazole)
Summary
In particular candidemia, are a growing problem in immunocompetent patients [1]. Concern exists on the value of evidence supporting recommendations for the optimal treatment of candidemia in non-neutropenic adult patients [1,2]. The primary recommendation for treatment of candidemia in non-neutropenic patients was administration of fluconazole or an echinocandin.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
